-$0.89 EPS Expected for Tricida Inc (TCDA) This Quarter

Brokerages forecast that Tricida Inc (NASDAQ:TCDA) will post ($0.89) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Tricida’s earnings, with estimates ranging from ($0.91) to ($0.87). The company is scheduled to report its next quarterly earnings results on Thursday, February 14th.

On average, analysts expect that Tricida will report full year earnings of ($2.92) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.90). For the next fiscal year, analysts forecast that the company will post earnings of ($3.45) per share, with EPS estimates ranging from ($3.50) to ($3.39). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Tricida.

Tricida (NASDAQ:TCDA) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.19.

A number of research analysts recently commented on the stock. Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, September 25th. Cowen reaffirmed a “buy” rating on shares of Tricida in a research report on Friday, November 9th.

Shares of NASDAQ:TCDA traded down $1.88 during trading hours on Wednesday, reaching $28.55. The stock had a trading volume of 105,443 shares, compared to its average volume of 84,844. Tricida has a 1 year low of $21.87 and a 1 year high of $40.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 12.68 and a quick ratio of 12.68.

In related news, insider Geoffrey M. Parker bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 13th. The shares were purchased at an average cost of $29.72 per share, with a total value of $148,600.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Large investors have recently modified their holdings of the stock. Strs Ohio acquired a new stake in Tricida during the 3rd quarter worth $100,000. Wells Fargo & Company MN acquired a new stake in Tricida during the 3rd quarter worth $170,000. American International Group Inc. acquired a new stake in Tricida during the 3rd quarter worth $237,000. Man Group plc acquired a new stake in Tricida during the 3rd quarter worth $253,000. Finally, Rhumbline Advisers acquired a new stake in Tricida during the 3rd quarter worth $270,000. Hedge funds and other institutional investors own 68.39% of the company’s stock.

Tricida Company Profile

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.

Recommended Story: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply